Capricor Therapeutics, Inc.
CAPR Healthcare Biotechnology
Capricor Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22.3 million, down 11.5% from fiscal 2023. In the quarter to June 2026, revenue fell 7.92%, EPS fell 22.8% and free cash flow fell 72.9%, each against the same quarter a year earlier.
Follow CAPR
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
318.13 | 151.52 | 39.49 | 41.42 | 34.89 | 32.67 | 9.89 | 7.54 | 14.87 | 17.54 |
Receivables |
0.06 | 10.37 | 10.37 | 0.55 | 0.39 | — | 0.09 | 0.20 | 0.34 | 0.22 |
Total current assets |
322.94 | 163.39 | 50.86 | 42.89 | 36.44 | 33.68 | 10.54 | 8.47 | 15.71 | 18.11 |
Property, Plant, Equpment (Net) |
18.31 | 5.56 | 5.56 | 4.59 | 1.80 | 0.85 | 0.44 | 0.57 | 0.37 | 0.44 |
Goodwill and Intangible Assets (Total) |
— | — | — | — | — | 0.00 | 0.01 | 0.05 | 0.09 | 0.14 |
Long-term assets (Other) |
1.16 | 0.22 | 0.27 | 0.27 | 0.28 | 0.09 | 0.12 | 0.15 | 0.10 | 0.06 |
Total non-current assets |
33.01 | 7.10 | 7.88 | 7.21 | 4.89 | 0.94 | 0.57 | 0.78 | 0.56 | 0.64 |
Total Assets |
355.95 | 170.48 | 58.73 | 50.09 | 41.33 | 34.62 | 11.11 | 9.25 | 16.27 | 18.75 |
Notes Payable |
— | — | — | — | — | 0.25 | — | — | — | — |
Accounts Payable |
1.65 | 3.28 | 6.25 | 4.92 | 3.72 | 2.72 | 0.90 | 1.26 | 1.67 | 3.53 |
Accrued Expenses |
15.56 | 4.91 | — | — | — | — | — | — | — | — |
Current Revenue (Deferred) |
12.00 | 12.00 | 24.27 | 17.98 | — | — | — | — | — | 1.37 |
Other current liabilities |
6.42 | — | — | 17.98 | 0.00 | 0.00 | — | — | — | 1.86 |
Total current liabilities |
35.84 | 21.03 | 31.27 | 23.59 | 4.13 | 2.97 | 0.90 | 1.26 | 1.67 | 4.90 |
Long Term Debt (Total) |
— | — | — | — | — | 0.07 | 3.38 | 3.38 | 3.38 | 13.91 |
Non-current Revenue (Deferred) |
— | — | — | 9.47 | — | — | — | — | — | — |
Non-current Liabilities (Other) |
— | 3.38 | 3.38 | 3.38 | 3.38 | 3.38 | 3.38 | 3.38 | 3.38 | 3.95 |
Total non-current liabilities |
14.32 | 3.99 | 4.86 | 14.72 | 5.83 | 3.45 | 3.38 | 3.38 | 3.38 | 17.86 |
Total liabilities |
50.16 | 25.02 | 36.13 | 38.31 | 9.96 | 6.42 | 4.27 | 4.63 | 5.05 | 22.75 |
Additional Paid In Capital |
610.33 | 344.22 | 181.70 | 148.74 | 139.40 | 116.22 | 81.22 | 71.34 | 62.74 | 49.95 |
Common Stock (Net) |
0.06 | 0.05 | 0.03 | 0.03 | 0.02 | 0.02 | 0.01 | 0.00 | 0.03 | 0.02 |
Retained Earnings |
(304.88) | (199.83) | (159.37) | (137.08) | (108.06) | (88.04) | (74.38) | (66.74) | (51.55) | (53.98) |
Common Equity (Total) |
305.79 | 145.46 | 22.60 | 11.79 | 31.37 | 28.20 | 6.84 | 4.62 | 11.23 | (4.00) |
Shareholders Equity (Total) |
305.79 | 145.46 | 22.60 | 11.79 | 31.37 | 28.20 | 6.84 | 4.62 | 11.23 | (4.00) |
Shareholders Equity and Liabilities (Total) |
355.95 | 170.48 | 58.73 | 50.09 | 41.33 | 34.62 | 11.11 | 9.25 | 16.27 | 18.75 |
Shares (Common) |
57.37 | 45.58 | 31.15 | 25.24 | 24.19 | 20.58 | 5.23 | 3.14 | 2.63 | 2.14 |
Shareholders Equity (Tangible) |
305.79 | 145.46 | 22.60 | 11.79 | 31.37 | 28.20 | 6.83 | 4.57 | 11.13 | (4.15) |
Net Debt |
(318.13) | (151.52) | (39.49) | (41.42) | (34.89) | (32.59) | (6.51) | (4.17) | (11.49) | (3.64) |
Total Debt |
— | — | — | 5.25 | 5.83 | 0.07 | 3.38 | 3.38 | 3.38 | 13.91 |